Suchergebnisse - "Usmani, Saad Z"

PubPharm (62)

1

Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk

enthalten in: Blood cancer journal | 2024

von Callander, N. | Silbermann, R. | Kaufman, J. | +33

2

Adjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data

enthalten in: Advances in therapy | 2024

von Durie, B. | Kumar, S. | Ammann, E. | +5

3

Daratumumab for patients with myeloma with early or late relapse after initial therapy : subgroup analysis of CASTOR and POLLUX

enthalten in: Blood advances | 2024

von Spencer, A. | Moreau, P. | Mateos, M. | +17

4

Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma : TAURUS Chart Review Study

enthalten in: Clinical lymphoma, myeloma & leukemia | 2024

von Gordan, L. | Tan, C. | Vescio, R. | +12

5

Expert Consensus on the Incorporation of Anti-CD38 Monoclonal Antibody Therapy Into the Management of Newly Diagnosed Multiple Myeloma

enthalten in: Clinical lymphoma, myeloma & leukemia | 2023

von Lonial, S. | Bowser, A. | Chari, A. | +3

6

Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab : part 3 of the open-label, multicenter, phase 1b PAVO study

enthalten in: Leukemia & lymphoma | 2023

von Nahi, H. | Usmani, S. | Mateos, M. | +10

7

Cross Fire : Daratumumab-Based Therapies Are Standard of Care in Newly Diagnosed Multiple Myeloma

enthalten in: Hematology/oncology and stem cell therapy | 2023

von Korde, N. | Usmani, S.

8

A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy

enthalten in: Leukemia & lymphoma | 2022

von Nath, K. | Shekarkhand, T. | Salcedo, M. | +19

9

Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma

enthalten in: Haematologica | 2022

von Usmani, S. | Nahi, H. | Legiec, W. | +25

10

Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma : A multi-institutional experience

enthalten in: American journal of hematology | 2022

von Mohan, M. | Becnel, M. | Shah, U. | +29

1
2
3
4
5
6
7
Nächster »
[7]